Leonardo Jaimes, MD

All articles by Leonardo Jaimes, MD

• Study finds prevalence of PBC has increased globally, especially in the Western Pacific

  The Western Pacific region experienced a marked increase in PBC prevalence in the last year, notes a new study.

• Volixibat for PBC-induced itching scores breakthrough therapy designation

  The FDA gave volixibat a special approval as a potential treatment for itching in patients with primary biliary cholangitis.

• Mapping PBC genetics: Which approach is better?

  A new study suggests which method is superior for detecting genetic variables associated with primary biliary cholangitis (PCB).

• FDA approves seladelpar to treat PBC

  The U.S. Food and Drug Administration gave accelerated approval for seladelpar to treat primary biliary cholangitis (PBC).

• New insights on the role of the gut microbiome in PBC therapy 

  Changes in the gut microbiome configuration could negatively affect the response to ursodeoxycholic acid (UDCA) treatment in patients with primary biliary cholangitis (PBC), according to a recently published study in Med. “These findings suggest that baseline microbial composition may predict treatment response and offer novel insights into PBC pathogenesis,” the study concluded. UDCA represents first-line […]

• Obeticholic acid improves outcomes for PBC patients in clinical trial

  Treatment with obeticholic acid (OCA) improved outcomes for primary biliary cholangitis (PBC) patients in a recent clinical trial.

• Obstacles in PBC care lead to delayed diagnosis and treatment

  A recent study found that some PBC patients face more barriers to care, leading to a delay in diagnosis and treatment.

• Mirum’s potential PBC therapy shows positive preliminary results

  A phase 2b clinical trial has shown positive preliminary results for volixibat intended for the treatment of PBC.

• FDA approves Ipsen’s Elafibranor for the treatment of PBC

  Ipsen’s Iqirvo (elafibranor) is the first new medicine approved in nearly a decade for the treatment of the PBC, according to a recent press release.

• Ipsen launches new trial studying potential PBC treatment

  Ipsen is recruiting participants for a trial assessing the safety and efficacy of elafibranor in primary biliary cholangitis (PBC).